



## Immunization Update 2017

Stephan L. Foster, Pharm.D., FAPhA  
CAPT(ret), U.S.P.H.S.  
Liaison Member, Advisory Committee on Immunization Practices



## Learning Objectives

At the end of the presentation, the participant will be able to:

1. Identify important recent changes to the immunization schedules for adults and children in the United States.
2. Discuss the epidemiology of recent outbreaks of vaccine-preventable diseases in the United States.
3. Incorporate recent ACIP recommendations into your practice.
4. List promising new vaccines in the development pipeline



## Self-Assessment Question #1

The new HPV9 vaccine schedule states that the 2 dose regimen should be given:

- A. Now and 1-2 months later to all patients 9 to 26 years of age
- B. now and 6-12 months later to all patients 9 to 26 years of age
- C. now and 1-2 months later to all patients 9 to less than 15 years of age
- D. now and 6-12 months later to all patients 9 to less than 15 years of age



## Self-Assessment Question #2

Which high risk patients should be given meningococcal B vaccine?

- A. All college students at age 18
- B. All adolescents at age 18
- C. All patients with complement deficiencies
- D. All patients with HIV/AIDS



## Self-Assessment Question #3

The FDA has approved meningococcal B vaccination with Trumenba as a:


- A. A single dose
- B. 2-dose series given at 0 and 1-2 months under certain circumstances
- C. 2-dose series given at 0 and 6 months under certain circumstances
- D. Must always be given as a 3 dose series at 0, 1-2 months, and 6 months.



## Self-Assessment Question #4

The ACIP has recommended that vaccination with LAIV (Flumist®) in the 2016-2017 influenza season


- A. Is preferred in children over IIV
- B. Has no preference from the ACIP over IIV
- C. Should not be given to anyone
- D. Should be given to all age eligible patients 2-49 years-old



## Self-Assessment Question #5

Vaxchora (Cholera vaccine Live, Oral- Pax Vax) is ACIP recommended for:





- All traveler outside the U.S.
- All traveler to countries with active cholera cases
- All travelers likely to have direct contact with cholera cases
- All travelers to countries with recent natural disasters



## Vaccine-Preventable Diseases


Disease	Max. Cases	Year	Cases 2012	Cases 2013	Cases 2014	Cases 2015	Cases 2016
Diphtheria	206,939	1921	1	0	1	0	0
Hib	~20,000	1980's	30	18	27	16	30
Measles	894,134	1941	55	184	628	188	83
Mumps	152,209	1968	229	438	1,151	422	5311
Pertussis	265,209	1934	48,277	24,231	28,660	13,004	4,988
Rubella	2.5 Million	1964-1965	9	9	8	4	2
CRS	~30,000		3	0	1	1	0
Tetanus	601	1948	37	19	21	17	7
Varicella	221,983	1984	13,447	9,987	9,058	5,373	2,843

Epidemiology and Prevention of Vaccine-Preventable Diseases. 12th ed.; May 2012  
JAMA. 2007;298:2155-263  
MMWR. Weekly / April 21, 2017 / 66(15)


## HPV9 Vaccine (Gardasil 9 – Merck)

- October 7, 2016 2 dose schedule approved by FDA
  - 2 doses may improve compliance
- Immunogenicity data presented to ACIP
  - Higher titers with vaccination than natural infections
  - Non-inferior antibody response in 9-14 year olds with 2 doses
    - Compared with 3 doses in 16-26 year olds
    - 0-6 months or 0-12 months schedule
    - 97.8%-100% seropositivity
    - Higher seroconversion in younger ages




## 2-Dose Schedules

- Minimum interval of 5 months for 2 doses mandatory
  - Memory B cells require 4-6 months to mature and differentiate into high-affinity B cells
  - 6-month interval allows last dose to efficiently reactivate memory B cells
- Persistence
  - No data from 2-dose studies






## HPV Recommendation







- 2-dose schedule at age 11-12 years
  - Include "less than 15 years"
  - Second dose 6-12 months after first
  - If interval less than 6 months, give third dose 6 months from first
- 3-dose schedule after 15<sup>th</sup> birthday
  - 0,1-2,6 months
- Special situations
  - If interrupted, doses based upon age of first dose
  - Minimum interval 5 months (FDA Approved)
  - Immunocompromised – 3-dose series
- Vote: Approved
- Note: HPV2 and HPV4 no longer available










## Meningococcal Vaccines

- Men ACWY Vaccines
  - Menomune – Sanofi Pasteur (MPSV4)
    - No longer available after last dose expires June-September 2017
  - Menactra – Sanofi Pasteur (MenACWY135-D)
  - Menveo – Novartis (MenACWY-135-CRM)
  - MenHibrix – GSK (HibMenCY-TT)
  - CDC-ACIP recommendations
    - Routine in adolescents
    - High-risk over 2 months of age
- MenB Vaccines
  - Both licensed by FDA for ages 10–25 years
  - Trumenba (Pfizer)
    - 3 dose series (0, 2, 6 months)
    - Components: FHBP subfamily Av2,3; subfamily B/v1
  - Bexsero (Novartis)
    - 2 dose series (0, 1–6 months)
    - Components: FHBP subfamily B/V1, NhbA, NadA, Por A1.4














## Possible Explanations



- Suboptimal performance of A/H1N1 vaccine strain
- Interference among virus when additional B strain added to quadrivalent
- Reduce immunogenicity of LAIV as a result of more highly vaccinated population in later years; more children were vaccine naïve in earlier years
- **Vote**
  - “In light of the evidence for poor effectiveness of LAIV in the United States over the last three influenza seasons (2013-2016), for the 2016-17 season, the ACIP makes the interim recommendation that LAIV should not be used.”
- MedImmune studying new vaccine strain
  - LAIV has 6 internal genes and 2 external genes (HA & NA) from circulating strains




## Recommendations for 2016-17 Influenza Season

- **No LAIV**
- Reiteration of vaccination of all persons 6 months and older
- Minor change in wording of vaccination timing
  - “Healthcare providers should offer vaccination by October, if possible. Vaccination should continue to be offered as long as influenza viruses are circulating.”
- Changes to egg allergy recommendations
- New vaccines
  - Flublok quadrivalent approved
- No vaccine preferences for one vaccine over another






**Adjuvanted IIV3 Vaccine**





- Developed by Novartis (now Seqirus)
- MF59 Adjuvant
  - Approved in Europe and Canada (30 countries)
    - 17 years of use with 76 million doses distributed
  - Enhances immune response
    - Squalene and surfactants
    - Recruits immune cells and activates T cells and B cells
    - 39 studies available
      - Immunological studies non-inferior
      - Generated higher AB titers
      - Higher immune response to drifted strains
  - Safety profile similar to non-adjuvanted vaccine
    - No narcolepsy reported
- Favorable by VERPAC for 65 years and older

**High-dose (HD) vs Standard Dose (SD)**  
Presented at Feb 2017 ACIP



- 50,000 residents in 823 nursing homes
  - Review of records- Not a prospective study
  - Study flaws noted
    - Severity of season
    - 10% of residents not vaccinated
    - H1N1 circulating (No difference if TIV or QIV)
    - Reduced hospitalizations not the only benefit of vaccination
  - Roughly equal numbers of HD and SD
- Number Need to Treat with HD to prevent 1 hospitalization = 81
  - 81 HD vaccines cost about \$2430 (81 x approximately \$30/vaccine)
  - Much less than one hospitalization





## Tdap in Pregnant Women

- Current recommendations 27-36 weeks
  - First passed in 2011
  - Coverage range 14-48% in United States
  - Safety monitoring reassuring – no increased risk
- New data on earlier vaccine administration
  - High maternal antibody concentrations
  - Higher anti-pertussis antibody in infant cord blood when vaccine given to mothers earlier
    - Perhaps due to longer exposure time during pregnancy
    - Vaccinating too early may not allow for sustained antibodies during first 2 months of life



## Tdap Recommendations

“Tdap should be administered between 27-36 weeks gestation, although it may be given at any time during pregnancy. Currently available data suggest that vaccinating earlier in the 27 through 36 week window will maximize passive antibody transfer to the infant.”




## New Influenza Vaccine Licensures

- **Afluria (Seqirus)**
  - **Quadrivalent**
    - Approved August 24, 2016 for ≥18 year olds
    - Studies for ≥6 months underway
  - TIV and QIV approved for PharmaJet
- **Fluad (Seqirus)**
  - **Trivalent**
    - Approved for adults 65 years and older
    - Adjuvanted with MP59
- **Flucelvax Quadrivalent (Seqirus)**
  - Approved May 23, 2016 for ≥ 4 years
- **Flublok Quadrivalent**
  - Approved October 7, 2016
- **FluLaval Quadrivalent**
  - Approved November 18, 2016 for use in younger children
  - Now persons **6 months** and older
  - Same dose (15mcc of each strain)



## Cholera



<http://www.who.int/wer/2015/wer9040.pdf>




## Vaxchora (PaxVax)

- Single oral dose given 10 days before travel
- Approved June 2016 for persons aged 18-64 years
  - Aid, refugee, and health care workers likely to have direct contact with bodily fluids in proximity to displaced populations, especially in crowded camps or impoverished areas
- Adverse effects
  - Tiredness, headache, abdominal pain, N/V, lack of appetite, diarrhea
- No data on this vaccine in:
  - Pregnancy, breastfeeding, immunocompromised, children, shedding/household transmission
- 80-90% effectiveness
  - Duration of protection: 3-6 months
  - No activity against E Coli for Travelers diarrhea

## ACIP Immunization Schedule for Adults, 2017










## Pharmacist Administered Influenza Vaccine

- Study using prescription database and BFRSS 2007-2013
- Results
  - Number vaccinations increased from 3.2 million to 20.9 million
  - No significant difference in adult vaccination rates
  - No observed difference in high-risk adult vaccination rates
- Conclusion
  - “...we do not observe substantial increases in adult immunizations vaccination rates.....which suggest that most of the people vaccinated by pharmacists would have been vaccinated anyway. The main benefit...a more convenient and flexible way to obtain an important health service”

McConeghy KW, Wing C. A national examination of pharmacy-based immunization statutes and their association with influenza vaccinations and preventive health. *Vaccine* 2016;34:3463-3468





## VACCINES IN THE PIPELINE




## Ebola Vaccine Trials


- Guinea and Sierra Leone Trial
  - recombinant vesicular stomatitis virus vaccine expressing the glycoprotein of Zaire Ebola virus
    - Protects against 1 or 5 strains of Ebola
  - Phase 3 trial –ring vaccination
    - Not placebo controlled- offered immediate vaccination or 21 day delay
  - 100% effective after 10 days
- Sierra Leone Trial – China CDC
  - Recombinant adenovirus type-5 vector based vaccine
  - Phase 2 trial
  - Safe and highly immunogenic
  - 85% decrease in response after 6 months
- Developed after peak of outbreaks
- Other vaccine trials ongoing which may interfere with overall result
- Duration of protection unknown



## RSV Vaccine


- No successful vaccine since virus discovery 1956
  - Monoclonal antibodies for high-risk infants
- First vaccine 1966
  - Formalin inactivated
  - More severe RSV disease than unvaccinated
- Novavax, Inc.
  - Completed Phase 3 trials in older adults
    - Initial results not good
    - Trials ongoing – differing formulations
  - Multiple studies ongoing
    - Maternal immunizations
    - Pediatrics






## Zoster Vaccines

- VZ12 (Merck)
  - Inactivated formulation of Zostavax
  - 4-dose series in persons >18 years of age
  - Ongoing Phase 3 efficacy trials
- HZ/su (GSK) – Shingrix
  - Inactivated, 2-dose series in persons
  - Efficacy
    - 97.2% ≥50 years
    - 89% ≥ 70 years
      - 70-79 years – 90.0%
      - ≥80 years – 89.1%
  - Submitted BLA to FDA October 2016




## Planned Studies With HZ/su

- Revaccination
  - Boostability at 5 and 10 years
  - Booster after live vaccine
- Co-administration
- Duration of protection
- Efficacy in select immunocompromised patients
- Impact on daily life
- Comparison study with live vaccine



## Dengue – Global 2013




- 3.2 million cases reported
- 50-100 mill estimated
- 9,000+ deaths

The color lines of the dengue and Zika viruses indicate areas of the world by the geographical limits of the vector and whether conditions for transmission of these agents. The tropical climate zone of dengue virus.


The locations and names shown on the map are not intended to represent the opinions of any member state on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the boundaries and the names of territories. Cities and named lines on maps represent approximate border lines for which there may not yet be full agreement.

World Health Organization  
Geneva, Switzerland  
© WHO 2014. All rights reserved.




## Dengue Vaccine

- Ideal vaccine must cover DENV 1-4 strains
- Dengvaxia (CYD-TDV)
  - Registered in several dengue endemic countries (not the US)
  - Live attenuated, recombinant, tetravalent
  - 3 SC doses 6 month intervals
  - 53%-93% vaccine efficacy for up to 3 years (early estimates)
  - May make infections worse in areas of low disease incidence.
- Several other candidate vaccines
  - Recombinant, DNA, VLP, virus-vectored, live-attenuated



## Zika Virus Update




- 4,835 cases in United States

States and Territories Reporting Zika Virus Disease  
Most reporting is from states with confirmed cases.

0-10  
11-20  
21-30  
31-40  
41-50  
51-60  
61-70  
71-80  
81-90  
91-100  
101-110  
111-120  
121-130  
131-140  
141-150  
151-160  
161-170  
171-180  
181-190  
191-200  
201-210  
211-220  
221-230  
231-240  
241-250  
251-260  
261-270  
271-280  
281-290  
291-300  
301-310  
311-320  
321-330  
331-340  
341-350  
351-360  
361-370  
371-380  
381-390  
391-400  
401-410  
411-420  
421-430  
431-440  
441-450  
451-460  
461-470  
471-480  
481-490  
491-500  
501-510  
511-520  
521-530  
531-540  
541-550  
551-560  
561-570  
571-580  
581-590  
591-600  
601-610  
611-620  
621-630  
631-640  
641-650  
651-660  
661-670  
671-680  
681-690  
691-700  
701-710  
711-720  
721-730  
731-740  
741-750  
751-760  
761-770  
771-780  
781-790  
791-800  
801-810  
811-820  
821-830  
831-840  
841-850  
851-860  
861-870  
871-880  
881-890  
891-900  
901-910  
911-920  
921-930  
931-940  
941-950  
951-960  
961-970  
971-980  
981-990  
991-1000  
1001-1010  
1011-1020  
1021-1030  
1031-1040  
1041-1050  
1051-1060  
1061-1070  
1071-1080  
1081-1090  
1091-1100  
1101-1110  
1111-1120  
1121-1130  
1131-1140  
1141-1150  
1151-1160  
1161-1170  
1171-1180  
1181-1190  
1191-1200  
1201-1210  
1211-1220  
1221-1230  
1231-1240  
1241-1250  
1251-1260  
1261-1270  
1271-1280  
1281-1290  
1291-1300  
1301-1310  
1311-1320  
1321-1330  
1331-1340  
1341-1350  
1351-1360  
1361-1370  
1371-1380  
1381-1390  
1391-1400  
1401-1410  
1411-1420  
1421-1430  
1431-1440  
1441-1450  
1451-1460  
1461-1470  
1471-1480  
1481-1490  
1491-1500  
1501-1510  
1511-1520  
1521-1530  
1531-1540  
1541-1550  
1551-1560  
1561-1570  
1571-1580  
1581-1590  
1591-1600  
1601-1610  
1611-1620  
1621-1630  
1631-1640  
1641-1650  
1651-1660  
1661-1670  
1671-1680  
1681-1690  
1691-1700  
1701-1710  
1711-1720  
1721-1730  
1731-1740  
1741-1750  
1751-1760  
1761-1770  
1771-1780  
1781-1790  
1791-1800  
1801-1810  
1811-1820  
1821-1830  
1831-1840  
1841-1850  
1851-1860  
1861-1870  
1871-1880  
1881-1890  
1891-1900  
1901-1910  
1911-1920  
1921-1930  
1931-1940  
1941-1950  
1951-1960  
1961-1970  
1971-1980  
1981-1990  
1991-2000  
2001-2010  
2011-2020  
2021-2030  
2031-2040  
2041-2050  
2051-2060  
2061-2070  
2071-2080  
2081-2090  
2091-2100  
2101-2110  
2111-2120  
2121-2130  
2131-2140  
2141-2150  
2151-2160  
2161-2170  
2171-2180  
2181-2190  
2191-2200  
2201-2210  
2211-2220  
2221-2230  
2231-2240  
2241-2250  
2251-2260  
2261-2270  
2271-2280  
2281-2290  
2291-2300  
2301-2310  
2311-2320  
2321-2330  
2331-2340  
2341-2350  
2351-2360  
2361-2370  
2371-2380  
2381-2390  
2391-2400  
2401-2410  
2411-2420  
2421-2430  
2431-2440  
2441-2450  
2451-2460  
2461-2470  
2471-2480  
2481-2490  
2491-2500  
2501-2510  
2511-2520  
2521-2530  
2531-2540  
2541-2550  
2551-2560  
2561-2570  
2571-2580  
2581-2590  
2591-2600  
2601-2610  
2611-2620  
2621-2630  
2631-2640  
2641-2650  
2651-2660  
2661-2670  
2671-2680  
2681-2690  
2691-2700  
2701-2710  
2711-2720  
2721-2730  
2731-2740  
2741-2750  
2751-2760  
2761-2770  
2771-2780  
2781-2790  
2791-2800  
2801-2810  
2811-2820  
2821-2830  
2831-2840  
2841-2850  
2851-2860  
2861-2870  
2871-2880  
2881-2890  
2891-2900  
2901-2910  
2911-2920  
2921-2930  
2931-2940  
2941-2950  
2951-2960  
2961-2970  
2971-2980  
2981-2990  
2991-3000  
3001-3010  
3011-3020  
3021-3030  
3031-3040  
3041-3050  
3051-3060  
3061-3070  
3071-3080  
3081-3090  
3091-3100  
3101-3110  
3111-3120  
3121-3130  
3131-3140  
3141-3150  
3151-3160  
3161-3170  
3171-3180  
3181-3190  
3191-3200  
3201-3210  
3211-3220  
3221-3230  
3231-3240  
3241-3250  
3251-3260  
3261-3270  
3271-3280  
3281-3290  
3291-3300  
3301-3310  
3311-3320  
3321-3330  
3331-3340  
3341-3350  
3351-3360  
3361-3370  
3371-3380  
3381-3390  
3391-3400  
3401-3410  
3411-3420  
3421-3430  
3431-3440  
3441-3450  
3451-3460  
3461-3470  
3471-3480  
3481-3490  
3491-3500  
3501-3510  
3511-3520  
3521-3530  
3531-3540  
3541-3550  
3551-3560  
3561-3570  
3571-3580  
3581-3590  
3591-3600  
3601-3610  
3611-3620  
3621-3630  
3631-3640  
3641-3650  
3651-3660  
3661-3670  
3671-3680  
3681-3690  
3691-3700  
3701-3710  
3711-3720  
3721-3730  
3731-3740  
3741-3750  
3751-3760  
3761-3770  
3771-3780  
3781-3790  
3791-3800  
3801-3810  
3811-3820  
3821-3830  
3831-3840  
3841-3850  
3851-3860  
3861-3870  
3871-3880  
3881-3890  
3891-3900  
3901-3910  
3911-3920  
3921-3930  
3931-3940  
3941-3950  
3951-3960  
3961-3970  
3971-3980  
3981-3990  
3991-4000  
4001-4010  
4011-4020  
4021-4030  
4031-4040  
4041-4050  
4051-4060  
4061-4070  
4071-4080  
4081-4090  
4091-4100  
4101-4110  
4111-4120  
4121-4130  
4131-4140  
4141-4150  
4151-4160  
4161-4170  
4171-4180  
4181-4190  
4191-4200  
4201-4210  
4211-4220  
4221-4230  
4231-4240  
4241-4250  
4251-4260  
4261-4270  
4271-4280  
4281-4290  
4291-4300  
4301-4310  
4311-4320  
4321-4330  
4331-4340  
4341-4350  
4351-4360  
4361-4370  
4371-4380  
4381-4390  
4391-4400  
4401-4410  
4411-4420  
4421-4430  
4431-4440  
4441-4450  
4451-4460  
4461-4470  
4471-4480  
4481-4490  
4491-4500  
4501-4510  
4511-4520  
4521-4530  
4531-4540  
4541-4550  
4551-4560  
4561-4570  
4571-4580  
4581-4590  
4591-4600  
4601-4610  
4611-4620  
4621-4630  
4631-4640  
4641-4650  
4651-4660  
4661-4670  
4671-4680  
4681-4690  
4691-4700  
4701-4710  
4711-4720  
4721-4730  
4731-4740  
4741-4750  
4751-4760  
4761-4770  
4771-4780  
4781-4790  
4791-4800  
4801-4810  
4811-4820  
4821-4830  
4831-4840  
4841-4850  
4851-4860  
4861-4870  
4871-4880  
4881-4890  
4891-4900  
4901-4910  
4911-4920  
4921-4930  
4931-4940  
4941-4950  
4951-4960  
4961-4970  
4971-4980  
4981-4990  
4991-5000  
5001-5010  
5011-5020  
5021-5030  
5031-5040  
5041-5050  
5051-5060  
5061-5070  
5071-5080  
5081-5090  
5091-5100  
5101-5110  
5111-5120  
5121-5130  
5131-5140  
5141-5150  
5151-5160  
5161-5170  
5171-5180  
5181-5190  
5191-5200  
5201-5210  
5211-5220  
5221-5230  
5231-5240  
5241-5250  
5251-5260  
5261-5270  
5271-5280  
5281-5290  
5291-5300  
5301-5310  
5311-5320  
5321-5330  
5331-5340  
5341-5350  
5351-5360  
5361-5370  
5371-5380  
5381-5390  
5391-5400  
5401-5410  
5411-5420  
5421-5430  
5431-5440  
5441-5450  
5451-5460  
5461-5470  
5471-5480  
5481-5490  
5491-5500  
5501-5510  
5511-5520  
5521-5530  
5531-5540  
5541-5550  
5551-5560  
5561-5570  
5571-5580  
5581-5590  
5591-5600  
5601-5610  
5611-5620  
5621-5630  
5631-5640  
5641-5650  
5651-5660  
5661-5670  
5671-5680  
5681-5690  
5691-5700  
5701-5710  
5711-5720  
5721-5730  
5731-5740  
5741-5750  
5751-5760  
5761-5770  
5771-5780  
5781-5790  
5791-5800  
5801-5810  
5811-5820  
5821-5830  
5831-5840  
5841-5850  
5851-5860  
5861-5870  
5871-5880  
5881-5890  
5891-5900  
5901-5910  
5911-5920  
5921-5930  
5931-5940  
5941-5950  
5951-5960  
5961-5970  
5971-5980  
5981-5990  
5991-6000  
6001-6010  
6011-6020  
6021-6030  
6031-6040  
6041-6050  
6051-6060  
6061-6070  
6071-6080  
6081-6090  
6091-6100  
6101-6110  
6111-6120  
6121-6130  
6131-6140  
6141-6150  
6151-6160  
6161-6170  
6171-6180  
6181-6190  
6191-6200  
6201-6210  
6211-6220  
6221-6230  
6231-6240  
6241-6250  
6251-6260  
6261-6270  
6271-6280  
6281-6290  
6291-6300  
6301-6310  
6311-6320  
6321-6330  
6331-6340  
6341-6350  
6351-6360  
6361-6370  
6371-6380  
6381-6390  
6391-6400  
6401-6410  
6411-6420  
6421-6430  
6431-6440  
6441-6450  
6451-6460  
6461-6470  
6471-6480  
6481-6490  
6491-6500  
6501-6510  
6511-6520  
6521-6530  
6531-6540  
6541-6550  
6551-6560  
6561-6570  
6571-6580  
6581-6590  
6591-6600  
6601-6610  
6611-6620  
6621-6630  
6631-6640  
6641-6650  
6651-6660  
6661-6670  
6671-6680  
6681-6690  
6691-6700  
6701-6710  
6711-6720  
6721-6730  
6731-6740  
6741-6750  
6751-6760  
6761-6770  
6771-6780  
6781-6790  
6791-6800  
6801-6810  
6811-6820  
6821-6830  
6831-6840  
6841-6850  
6851-6860  
6861-6870  
6871-6880  
6881-6890  
6891-6900  
6901-6910  
6911-6920  
6921-6930  
6931-6940  
6941-6950  
6951-6960  
6961-6970  
6971-6980  
6981-6990  
6991-7000  
7001-7010  
7011-7020  
7021-7030  
7031-7040  
7041-7050  
7051-7060  
7061-7070  
7071-7080  
7081-7090  
7091-7100  
7101-7110  
7111-7120  
7121-7130  
7131-7140  
7141-7150  
7151-7160  
7161-7170  
7171-7180  
7181-7190  
7191-7200  
7201-7210  
7211-7220  
7221-7230  
7231-7240  
7241-7250  
7251-7260  
7261-7270  
7271-7280  
7281-7290  
7291-7300  
7301-7310  
7311-7320  
7321-7330  
7331-7340  
7341-7350  
7351-7360  
7361-7370  
7371-7380  
7381-7390  
7391-7400  
7401-7410  
7411-7420  
7421-7430  
7431-7440  
7441-7450  
7451-7460  
7461-7470  
7471-7480  
7481-7490  
7491-7500  
7501-7510  
7511-7520  
7521-7530  
7531-7540  
7541-7550  
7551-7560  
7561-7570  
7571-7580  
7581-7590  
7591-7600  
7601-7610  
7611-7620  
7621-7630  
7631-7640  
7641-7650  
7651-7660  
7661-7670  
7671-7680  
7681-7690  
7691-7700  
7701-7710  
7711-7720  
7721-7730  
7731-7740  
7741-7750  
7751-7760  
7761-7770  
7771-7780  
7781-7790  
7791-7800  
7801-7810  
7811-7820  
7821-7830  
7831-7840  
7841-7850  
7851-7860  
7861-7870  
7871-7880  
7881-7890  
7891-7900  
7901-7910  
7911-7920  
7921-7930  
7931-7940  
7941-7950  
7951-7960  
7961-7970  
7971-7980  
7981-7990  
7991-8000  
8001-8010  
8011-8020  
8021-8030  
8031-8040  
8041-8050  
8051-8060  
8061-8070  
8071-8080  
8081-8090  
8091-8100  
8101-8110  
8111-8120  
8121-8130  
8131-8140  
8141-8150  
8151-8160  
8161-8170  
8171-8180  
8181-8190  
8191-8200  
8201-8210  
8211-8220  
8221-8230  
8231-8240  
8241-8250  
8251-8260  
8261-8270  
8271-8280  
8281-8290  
8291-8300  
8301-8310  
8311-8320  
8321-8330  
8331-8340  
8341-8350  
8351-8360  
8361-8370  
8371-8380  
8381-8390  
8391-8400  
8401-8410  
8411-8420  
8421-8430  
8431-8440  
8441-8450  
8451-8460  
8461-8470  
8471-8480  
8481-8490  
8491-8500  
8501-8510  
8511-8520  
8521-8530  
8531-8540  
8541-8550  
8551-8560  
8561-8570  
8571-8580  
8581-8590  
8591-8600  
8601-8610  
8611-8620  
8621-8630  
8631-8640  
8641-8650  
8651-8660  
8661-8670  
8671-8680  
8681-8690  
8691-8700  
8701-8710  
8711-8720  
8721-8730  
8731-8740  
8741-8750  
8751-8760  
8761-8770  
8771-8780  
8781-8790  
8791-8800  
8801-8810  
8811-8820  
8821-8830  
8831-8840  
8841-8850  
8851-8860  
8861-8870  
8871-8880  
8881-8890  
8891-8900  
8901-8910  
8911-8920  
8921-8930  
8931-8940  
8941-8950  
8951-8960  
8961-8970  
8971-8980  
8981-8990  
8991-9000  
9001-9010  
9011-9020  
9021-9030  
9031-9040  
9041-9050  
9051-9060  
9061-9070  
9071-9080  
9081-9090  
9091-9100  
9101-9110  
9111-9120  
9121-9130  
9131-9140  
9141-9150  
9151-9160  
9161-9170  
9171-9180  
9181-9190  
9191-9200  
9201-9210  
9211-9220  
9221-9230  
9231-9240  
9241-9250  
9251-9260  
9261-9270  
9271-9280  
9281-9290  
9291-9300  
9301-9310  
9311-9320  
9321-9330  
9331-9340  
9341-9350  
9351-9360  
9361-9370  
9371-9380  
9381-9390  
9391-9400  
9401-9410  
9411-9420  
9421-9430  
9431-9440  
9441-9450  
9451-9460  
9461-9470  
9471-9480  
9481-9490  
9491-9500  
9501-9510  
9511-9520  
9521-9530  
9531-9540  
9541-9550  
9551-9560  
9561-9570  
9571-9580  
9581-9590  
9591-9600  
9601-9610  
9611-9620  
9621-9630  
9631-9640  
9641-9650  
9651-9660  
9661-9670  
9671-9680  
9681-9690  
9691-9700  
9701-9710  
9711-9720  
9721-9730  
9731-9740  
9741-9750  
9751-9760  
9761-9770  
9771-9780  
9781-9790  
9791-9800  
9801-9810  
9811-9820  
9821-9830  
9831-9840  
9841-9850  
9851-9860  
9861-9870  
9871-9880  
9881-9890  
9891-9900  
9901-9910  
9911-9920  
9921-9930  
9931-9940  
9941-9950  
9951-9960  
9961-9970  
9971-9980  
9981-9990  
9991-10000

https://www.cdc.gov/zika/intheus/maps-zika-us.html. Accessed January 5, 2017



## Inactivated Zika Vaccine Trial Started

- Induced neutralizing antibodies in rhesus monkeys
- First of 5 phase 1 trials (Military)
- 75 participants with no previous infections by flaviviruses
- To be completed by fall 2018
- Additional trials to start soon

Health Agencies